drugset / Trial / NCT00216476
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate whether a long-acting injectable formulation of risperidone provides better effectiveness over 2 years, as measured by the time to relapse, compared with quetiapine tablets in a routine psychiatric care setting. Aripiprazole will be investigated in a descriptive manner.
Timeline
- Start
- 2004-10
- Primary completion
- 2007-11
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | 10 mg | Oral |
| Subject | Aripiprazole | Other / unclassified | 30 mg | Oral |
| Comparator | Quetiapine | Small molecule | 300 mg | Oral |
| Comparator | Quetiapine | Small molecule | 400 mg | Oral |
| Subject | Risperidone | Other / unclassified | 25 mg | Intramuscular |